Home » Newsletters » BioWorld Science

BioWorld Science

May 25, 2021

View Archived Issues

"Invisible" T cells bioengineered from human iPSCs

New purine-nucleoside phosphorylase inhibitors identified at IOCB

Jiangsu Hansoh Pharmaceutical, Shanghai Hansoh Biomedical patent 5-HT2A antagonists/DRD3 agonists

Ribon Therapeutics discovers TIPARP inhibitors

New N-acetyl-beta-D-glucosaminidase inhibitors described by Biogen

Bristol Myers Squibb identifies new TLR7/8/9 antagonists

Promising data from PDAC arm of the ongoing CANFOUR study of nadunolimab plus chemotherapy

Regulus reports updated results from phase Ib study of RGLS-4326 in ADPKD

Long-term reduced dose regimen with sargramostim shows improved safety in patients with PD

New plasma proteomic biomarkers of OCAD among patients with diabetes

HMGCR variant linked to diabetes in premature triple-vessel disease patients

FXIa inhibitor BMS-986177 well tolerated in patients with renal impairment

Pfizer evaluates 20vPnC coadministered with booster dose of COVID-19 vaccine

Pilot study evaluates NT-I7 in progressive multifocal leukoencephalopathy

Phase IIb study of aldafermin in F2/F3 NASH does not meet primary endpoint

SZN-1326 induces mucosal healing in an acute injury model of IBD

FDA approves IND for phase I trial of Scopus' CpG-STAT3siRNA

Cynata begins MEND trial of Cymerus mesenchymal stem cells in respiratory failure

Initial data reported from phase Ib study of Betalutin with rituximab in second-line FL

Nasally administered foralumab studied in secondary progressive multiple sclerosis

Kiromic submits IND for CAR T-cell therapy KB-ISM

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 31, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...